ENO2 and lung cancer: Therefore, the combination of early lung cancer autoantibodies and several serum tumor markers commonly used in clinical practice, namely CYFRA21-1, CEA, SCCA, and NSE, can further enable effective differentiation between patients with early lung cancer and patients with benign lung nodules.